# The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

> **NCT00990808** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 46 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** anacetrapib
- **DRUG:** Comparator: atorvastatin
- **DRUG:** Comparator: placebo to MK0859
- **DRUG:** Comparator: placebo to atorvastatin

## Key facts

- **NCT ID:** NCT00990808
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990808, "The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00990808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*